Compare Annaly Capital Management, Inc. (NLY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs TG Therapeutics Inc — how do they compare? Annaly Capital Management, Inc. trades at $18.3 (market cap $13.77B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Annaly Capital Management, Inc. is the larger of the two by market cap, and Annaly Capital Management, Inc. pays a 16.42% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 91 Days and TG Therapeutics Inc for 16 Days on average.
| NLY | TGTX | |
|---|---|---|
Market Cap | $13.77B | $8.16B |
Volume | 21,283,879 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $59.06 |
52-Week Low | $17.93 | $26.94 |
Typical Hold Time | 91 Days | 16 Days |
Enterprise Value | $135.80B | $8.37B |
Dividend Yield | 16.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLY trades at $18.27, up 1.9% with strong recent earnings beats (Q2 2026 EPS of $0.79 vs. $0.751 expected). The stock shows bearish technical signals but attractive valuation with P/E of 4.41 and P/B of 0.91. Recent news highlights the 14.7% dividend yield and portfolio expansion to $107 billion in 2026. Cash flow trends show improving net cash flow from $550M in 2025 to projected $853M in 2026.
NLY presents a high-yield opportunity with sustainable dividends supported by strong portfolio growth, though technical indicators signal caution. The stock trades at a discount to analyst consensus target of $22.00 (57% buy ratings). Key risks include interest rate sensitivity and mortgage spread volatility, but fundamental strength supports the current yield.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
